Optimum TAVI System
Symptomatic, Severe Aortic Stenosis
CE Mark TrialActive
Key Facts
Indication
Symptomatic, Severe Aortic Stenosis
Phase
CE Mark Trial
Status
Active
Company
About Thubrikar Aortic Valve
Thubrikar Aortic Valve is a privately-held, US-based innovator targeting the transcatheter aortic valve replacement (TAVR) market with a focus on long-term durability, a key unmet need. The company's lead product, the Optimum TAVI System, is currently in clinical trials in Europe (for CE Mark) and has demonstrated promising early clinical results in a 12-patient study, with one First-in-Human patient exceeding 6 years of follow-up. The company has a strategic manufacturing and commercialization partnership with Labcor Laboratórios for South America and is positioning its valve as a potential new standard of care for a broader patient population, including younger patients.
View full company profile